Symbol
Alnylam Pharmaceuticals, Inc.
Full name of the company.
MEDICAL-BIOMED/GENETICS
Industry name
DRUGS
Major industry name
Medical
Sector name
$332.61
Current price of the stock
$2M
Trading volume of the stock
$43.2B
Market capitalization of the company
Large Cap
Category of market capitalization
32.56%
Long-term growth mean estimate
4.35
Mean analyst rating
54.51%
Potential price appreciation based on analyst price targets
9.33%
Percentage difference of EPS surprise
-
Dividend change over 1 year
$0.00
Shows the amount of dividend paid
4.45
Total debt to total equity ratio
2.54
Current ratio
83.98%
Gross profit margin
29.46%
Operating profit margin
29.46%
Earnings before interest and taxes (EBIT) margin
-
Earnings before interest, taxes, depreciation, and amortization (EBITDA) margin
19.13%
Pretax profit margin
20.10%
Net profit margin
107.35%
Measures profitability relative to shareholders' equity
107.35%
ROE excluding intangible assets
5.18%
Measures profitability relative to total assets
19.71%
Measures profitability relative to invested capital
0.26
Asset turnover ratio
2.66
Inventory turnover ratio
1.29
Receivables turnover ratio
69.52
Average number of days it takes to collect receivables
1366.96
Measures valuation relative to earnings
-96.15
P/E based on future earnings estimates
13.45
Measures valuation relative to sales
177.16
Measures valuation relative to book value
163.88
Measures valuation relative to operating cash flow
274.61
Measures valuation relative to free cash flow
0
Indicates company's M&A activity
© 2022 - 2026 QuantStrategy.io, Arizet Labs, LLC